Haemonetics HAE Blood Center — SG&A

Other segment segments

Similar metrics at other companies

ARWROperating Segment — SG&A

$41.74M+47.0%

IFFHealth & Biosciences — Selling and administrative expenses

$92M+13.6%

ALife Sciences and Diagnostics Markets — Selling, General and Administrative Expense

$170M+8.3%

ASHLife Sciences — Selling General And Administrative Expense

$20M+5.3%

LENSouth Central — SG&A

$107.63M+13.5%

BSXCardiovascular — Selling, general and administrative expenses

$959M+9.9%

Questions, answered.

What is Haemonetics's blood center — SG&A?

Haemonetics (HAE) reported blood center — SG&A of $13.48M in Q1 2026.

How has Haemonetics's blood center — SG&A changed year-over-year?

Haemonetics's blood center — SG&A decreased by 9.6% year-over-year, from $14.91M to $13.48M.

What is the long-term trend for Haemonetics's blood center — SG&A?

Over 3 years (2023 to 2026), Haemonetics's blood center — SG&A has grown at a -9.9% compound annual growth rate (CAGR), from $74.02M to $54.13M.

What does blood center — SG&A mean?

Includes all non-production operating expenses such as sales, marketing, legal, and general management costs associated with the Blood Center segment. This metric reflects the overhead burden required to support and grow the segment's market presence. High levels relative to revenue may indicate inefficiencies in administrative scaling or high customer acquisition costs.